ABSTRACT
Objective To explore the effect of Kang′ai injection in the chemotherapy treatment of gastroin-testinal cancer.Methods 97 patients with gastrointestinal cancer were divided into the control group(49 cases) and the observation group(48 cases) in accordance with the random number table.The control group received common chemotherapy treatment,while the observation group was plused Kang'ai injection based on the same treatment.The near time clinical efficacy and survival rate in three years between the two groups were compared.Results The near time total effective rate of the observation group was 89.58%, which was significantly higher than 71.43% of the control group(χ2 =19.278,P<0.05).The improvement rate of quality of life in the observation group was 68.75%, which was significantly higher than 30.61% of the control group(χ2 =10.876,P<0.05).The reduction rate of quality of life in the observation group was 10.42%,which was significantly lower than 34.69%of the control group (χ2 =12.674,P<0.05).About adverse reactions rate above Ⅲ°,the gastrointestinal in the observation group was 6.25%,which was significantly lower than 22.45%of the control group(χ2 =14.523,P<0.05).The blood adverse reactions rate in the observation group was 0.00%,which was significantly lower than 12.24% of the control group (χ2 =17.795,P <0.05).The survival rates of 1,2,3 years in the observation group were 91.67%,75.00%, 60.42%,respectively,which were significantly higher than 77.55%,59.18%,34.69% in the control group(χ2 =9.547,13.697,15.862,all P<0.05).Conclusion Kang′ai injection can improve the tolerance of gastrointestinal cancer to chemotherapy treatment,reduce adverse reactions rate,improve quality of life and prolong survival.
ABSTRACT
Objective To observe the effects of different antithrombotic interventions on the changes of plasma lysophosphatidic acid (LPA) level in patients with nonvalvular atrial fibrillation (NVAF) and to provide the basis for clinical antithrombotic therapy. Methods A total of 235 patients with NVAF who did not receive antithrombotic therapy diagnosed by clinical and auxiliary examinations were randomly allocated to receive aspirin (100 mg/d) plus dipyridamole (100 mg/d) (n =76), aspirin (100 mg/d) plus fixed-dose warfarin (1.25 mg/d) (n =79), and dose-adjusted warfarin (international normalized ratio (INR) range of 1.5 to 2. 1) (n =80). They gore redivided into <60, 60-75, and ≥76 year-old groups according to their age. The plasma LPA levels were measured and compared before treatment and 2 and 6 weeks after treatment. Results 1he plasma LPA levels were decreased more significantly in the aspirin plus fixed-dose group than those in the aspirin plus dipyridamole and dose-adjusted warfarin groups (all P < 0.01). Two and 6 weeks after treatment with aspirin plus dipyridamole in the < 60 year-old group, the plasma LPA levels were significantly lower than those before treatment (all P<0. 01). Two and6 weeks after treatment with aspirin plus fixed-dose warfarin in the < 60 year-old group, the plasma LPA levels were significantly lower than those before treatment (all P <0. 01). Two and 6 weeks after treatment with aspirin plus fixed-dose warfarin in the 60-75 year-old group, the plasma LPA levels were significantly lover than those before treatment (all P <0.01). Two and 6 weeks after the treatment with dose-adjusted warfarin (INR 1.5-2. 1) in patients in each age group, the plasma LPA levels were significantly lower than those before treatment. Conclusions 1he different antithromhotic therapeutic modalities have different effects on platelet activation in patients with NVAF in different age groups. The patients in the < 60 year-old group can receive aspirin plus dipyridamole, the patients in the < 75 year-old group can receive aspirin plus fix-dose warfarin, and the patients > 75 year-old, dose-adjusted warfarin (INR 1. 5-2. 1) should he recommend.
ABSTRACT
Objective To investigate the changes of plasma lysephosphatidic acid (LPA) or acidic phospholipids (AP) levels in patients with nonvalvular atrial fibrillation(NVAF) or NVAF associated with silent brain infarction (SBI) and to provide biochemistry evidence to antithrombotic therapy. Methods Plasma LPA/AP levels was examined in blood freshly sampled in 235 cases of NVAF who were not receiving any antithrombotic therapy, 116 cases SBI who were not with NVAF and 120 cases healthy volunteers as control enrolled in the LPA and stroke prevention study. Plasma LPA was assayed by measuring its inorganic phosphorus after separation by chromatograph. Meanwhile, the platelet activation in NVAF or (and) SBI were observed. Results SBI was found in 31.5% of the participants with NVAF, and in 37.6% of the elderly NVAF subjects (age60 years old). LPA/AP levels were significantly increased in NVAF with SBI group((3.78±0.61) μmol/L) compared with controls ((2.66±0.49) μmol/L, 95% CI 3.47-4.21,P = 0.000), NVAF without SBI group ((3.29±0.57) μmol/L, 95 % CI 3.01-3.76, P = 0.008), SBI without NVAF group((3.17±0.54) μmol/L, P=0.004). The platelet activation was significantly higherin NVAF with SBI group, the odds ratio (95% CI) was 21.39(10.17 to 45.02),than those in NVAF without SBI group (P<0.01). Conclusion The plasma LPA/AP levels were significantly elevated in NVAF or NVAF with SBI, NVAF contributes to the risk of SBI. Platelet activation may play an important role in the pathogenesis of thromboembolism in NVAF and the measurement of LPA reflects activation of platelets in vivo and may be a useful marker for the diagnosis of thrombosis or prothrombotic states.Consideration of the role of antiplatelet therapy should be given when choosing antithrombotic therapy to NVAF-associated ischemic stroke.
ABSTRACT
With the rapid development of medicine,medical ethics and medical philosophy have also made a far step forward.Under the new historical conditions,they are endowed with a new scientific connotation,which is elaborated in the modern version of Hippocratic Oath.